A PEG-Fmoc conjugate as a nanocarrier for paclitaxel

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7146-7156

  Zhang, Peng ^a,b   Huang, Yixian ^a,b   Liu, Hao ^c   Marquez, Rebecca T ^c   Lu, Jianqin ^a,b   Zhao, Wenchen ^a   Zhang, Xiaolan ^a,b   Gao, Xiang ^a,b   Li, Jiang ^a,b   Venkataramanan, Raman ^a   Xu, Liang ^c   Li, Song ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

9 Fluorenylmethoxycarbonyl; Cancer therapy; Drug delivery; Drug carrier interaction; Micelle; Paclitaxel

Indexed keywords

AMINO ACIDS; DRUG DELIVERY; MICELLES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

9-FLUORENYLMETHOXYCARBONYL; CANCER THERAPY; CHEMOTHERAPEUTIC AGENTS; DRUG-CARRIER INTERACTION; FLUORESCENCE QUENCHING; NEAR-INFRARED FLUORESCENCE IMAGING; PACLITAXEL; SUSTAINED RELEASE KINETICS;

DRUG INTERACTIONS;

9 FLUORENYLMETHOXYCARBONYL; MACROGOL 5000; NANOCARRIER; PACLITAXEL; UNCLASSIFIED DRUG; DRUG CARRIER; MICELLE; NANOPARTICLE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; FEMALE; FLUORESCENCE; FLUORESCENCE QUENCHING; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; MICELLE; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOPARTICLES; PACLITAXEL; POLYMERS;

EID: 84902078210     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.108     Document Type: Article

References (33)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
2. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
3. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
4. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2-25.
5. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
6. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl 2009, 48:872-897.
7. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
8. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
9. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6:714-729.
10. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
11. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
12. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
13. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
14. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. JControl Release 2001, 73:137-172.
15. Lukyanov A.N., Torchilin V.P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004, 56:1273-1289.
16. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. JControl Release 2005, 109:169-188.
17. Huh K.M., Lee S.C., Cho Y.W., Lee J., Jeong J.H., Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. JControl Release 2005, 101:59-68.
18. Kim J.Y., Kim S., Pinal R., Park K. Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. JControl Release 2011, 152:13-20.
19. Yoon H.Y., Saravanakumar G., Heo R., Choi S.H., Song I.C., Han M.H., et al. Hydrotropic magnetic micelles for combined magnetic resonance imaging and cancer therapy. JControl Release 2012, 160:692-698.
20. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. JControl Release 2004, 100:247-256.
21. Yoo H.S., Park T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. JControl Release 2004, 96:273-283.
22. Gao X., Huang Y., Makhov A.M., Epperly M., Lu J., Grab S., et al. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Mol Pharm 2013, 10:187-198.
23. Zhang P., Lu J., Huang Y., Zhao W., Zhang Y., Zhang X., et al. Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. AAPS J 2014, 16:114-124.
24. Zhang Y., Gu H., Yang Z., Xu B. Supramolecular hydrogels respond to ligand-receptor interaction. JAm Chem Soc 2003, 125:13680-13681.
25. Castelletto V., Moulton C.M., Cheng G., Hamley I.W., Hicks M.R., Rodger A., et al. Self-assembly of Fmoc-tetrapeptides based on the RGDS cell adhesion motif. Soft Matter 2011, 7:11405-11415.
26. Jayawarna V., Ali M., Jowitt T.A., Miller A.E., Saiani A., Gough J.E., et al. Nanostructured hydrogels for three-dimensional cell culture through self-assembly of fluorenylmethoxycarbonyl-dipeptides. Adv Mater 2006, 18:611-614.
27. Shirai K., Matsuoka M., Fukunishi K. Fluorescence quenching by intermolecular pi-pi interactions of 2,5-bis(N,N-dialkylamino)-3,6-dicyanopyrazines. Dyes Pigments 1999, 42:95-101.
28. Rowinsky E.K., Donehower R.C. Drug-therapy - paclitaxel (taxol). New Engl J Med 1995, 332:1004-1014.
29. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
30. Bertrand N., Leroux J.C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. JControl Release 2012, 161:152-163.
31. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007, 59:718-728.
32. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
33. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. JControl Release 2010, 145:182-195.